Fundraising Fox

Merus

Utrecht, NL · 4 known investors

merus.nl ↗

Merus develops multispecific antibodies (Biclonics and Triclonics) that bind multiple cancer antigens to treat oncology indications. The company's lead candidate, petosemtamab, is in clinical development for head and neck cancer and colorectal cancer.

BiotechMedical Devicesin /merus

Founders & leadership

MT
Mark ThrosbyExecutive Officer
GD
Gregory D. PerryDirector
MT
Mark T. IwickiDirector
LM
Lionel M.S. CarnotDirector
HL
Hui LiuExecutive Officer
WB
Wolfgang BertholdDirector
AM
Anand MehraDirector
JC
John CrowleyExecutive Officer
JP
John P. de KoningDirector
LA
L. Andres SirulnikExecutive Officer
TL
Ton LogtenbergExecutive Officer, Director
LB
Lex BakkerExecutive Officer

Investors · 4

Avoro Capital AdvisorsNew York
Pfizer Venture Investments$5M – $20M
RA CapitalBoston
Sofinnova VenturesMenlo Park · $100K – $15M

Reported raises · per SEC filings

Form D private placements
▶$15MraisedJan 2019 · 1 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Ton LogtenbergExecutive Officer, Director
  • Gregory D. PerryDirector
  • Lex BakkerExecutive Officer
  • Anand MehraDirector
  • Mark ThrosbyExecutive Officer
  • Russell GreigDirector
  • Mark T. IwickiDirector
  • John De KruifExecutive Officer
  • John P. de KoningDirector
  • Len KanavyDirector
  • Hui LiuExecutive Officer
  • L. Andres SirulnikExecutive Officer
  • Peter SilvermanExecutive Officer
Offering amount
$15M
Amount sold
$15M
First sale
Dec 2018
Incorporated
Other, Netherlands
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$55.8MraisedFeb 2018 · 9 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Mark ThrosbyExecutive Officer
  • Gregory D. PerryDirector
  • Mark T. IwickiDirector
  • Lionel M.S. CarnotDirector
  • Hui LiuExecutive Officer
  • Wolfgang BertholdDirector
  • Anand MehraDirector
  • John CrowleyExecutive Officer
  • John P. de KoningDirector
  • L. Andres SirulnikExecutive Officer
  • Ton LogtenbergExecutive Officer, Director
  • Lex BakkerExecutive Officer
Offering amount
$55.8M
Amount sold
$55.8M
First sale
Feb 2018
Incorporated
Other, Netherlands
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$80MraisedJan 2017 · 1 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Anand MehraDirector
  • Wolfgang BertholdDirector
  • Shelley MargetsonExecutive Officer
  • Mark T. IwickiDirector
  • Gregory D. PerryDirector
  • Jack B. NielsenDirector
  • Lionel M.S. CarnotDirector
  • Ton LogtenbergExecutive Officer
  • John P. de KoningDirector
Offering amount
$80M
Amount sold
$80M
First sale
Jan 2017
Incorporated
Other, Netherlands
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

In the news